Australia's most trusted
source of pharma news
Thursday, 18 December 2025
Posted 17 December 2024 PM
Pfizer has cut its 2026 revenue forecast thanks to an expected US$1.5 billion decline in sales of its COVID products plus a further $1.5 billion hit from loss of exclusivity, sending its share price tumbling.
Growth is likely to elude the company for some time yet with drugs in its portfolio coming off patent set to cost an eye-watering US$17 billion by 2030.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.